Quantcast
Last updated on April 20, 2014 at 21:20 EDT

Latest AbbVie Stories

2014-04-16 12:30:01

- Scholarship recognizes 40 exceptional students with cystic fibrosis (CF) who serve as role models for the community through academic excellence, creativity and community service NORTH CHICAGO, Ill., April 16, 2014 /PRNewswire/ -- AbbVie today announced that undergraduate and graduate students living with cystic fibrosis (CF) can now apply for the 2014 AbbVie CF Scholarship, which honors young adults with CF as they pursue higher education. Students can apply for the scholarship...

2014-04-15 08:29:16

Trial Will Evaluate Investigational Compound's Efficacy and Safety as an Addition to Standard Chemotherapy in Previously-Untreated Patients NORTH CHICAGO, Ill., April 15, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced the initiation of a global Phase III clinical trial evaluating the safety and efficacy of its investigational compound, veliparib (ABT-888), in patients with previously untreated locally advanced or metastatic squamous non-small cell lung cancer (NSCLC). The trial...

2014-04-12 00:21:23

- In patients with compensated liver cirrhosis and genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, a difficult-to-treat population, TURQUOISE-II demonstrated SVR(12) rates of 91.8 and 95.9 percent after 12 and 24 weeks of treatment, respectively LONDON, April 12, 2014 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced that new, detailed results from its hepatitis C development program will be presented today at the International Liver Congress(TM) (ILC) 2014. Data from a pivotal phase...

2014-04-11 00:21:52

-SVR(12) rates of 96 percent were achieved in both SAPPHIRE-I (new to therapy) and SAPPHIRE-II (treatment-experienced with pegylated interferon and ribavirin) in adult patients with genotype 1 chronic hepatitis C virus infection LONDON, April 11, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced that detailed results from its phase III pivotal study, SAPPHIRE-I, will be presented today at the International Liver Congress(TM) (ILC) 2014 and featured in the ILC press conference....

2014-04-07 08:30:18

NORTH CHICAGO, Ill., April 7, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its first-quarter 2014 financial results on Friday, April 25, 2014, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern). It will be accessible through AbbVie's Investor Relations website at www.abbvieinvestor.com. An archived edition of the call will be available after 11 a.m. Central time. About AbbVieAbbVie is a global,...

2014-03-27 12:31:03

LONDON, March 27, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Global and China Monoclonal Antibody Industry Report, 2013-2017 Currently, monoclonal antibody agents have been successfully used in the treatment of tumors, cancers and other serious diseases as a heavyweight in the biopharmaceutical industry. In 2009-2012, the market size of monoclonal antibody agents grew at a CAGR of 13%, far higher than the overall growth rate of...

2014-03-24 04:22:12

NORTH CHICAGO, Ill., March 24, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) will present new data from its phase III hepatitis C development program at the 2014 International Liver Congress(TM) (ILC) in London, April 9-13. Detailed results from the SAPPHIRE-I, SAPPHIRE-II, PEARL-III, and TURQUOISE-II studies will be presented at the ILC on April 10-12. In presentations at the ILC, investigators will share detailed data results of four studies from AbbVie's phase III clinical trial program, the...

2014-03-03 16:25:42

-- SVR(12) rates of 99 percent with and without ribavirin were achieved in genotype 1b patients new to treatment BOSTON, March 3, 2014 /PRNewswire/ -- The first detailed results from AbbVie's (NYSE: ABBV) pivotal phase III study, PEARL-III, were presented today as part of the 21st Conference on Retroviruses and Opportunistic Infections (CROI) press conference and will also be presented as a late-breaker at the conference on March 4. PEARL-III evaluated the efficacy and safety of 12...

2014-02-26 08:28:26

NORTH CHICAGO, Ill., Feb. 26, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Barclays Global Healthcare Conference 2014 on Wednesday, March 12, 2014. Bill Chase, executive vice president and chief financial officer, will take part in a question and answer session at 7:30 a.m. Central time. A live audio webcast of the question and answer session will be accessible through AbbVie's Investor Relations Web site at www.abbvieinvestor.com. An archived edition of the...

2014-02-20 04:20:55

-- More than 200 artists inspired by patients in more than 40 countries NORTH CHICAGO, Ill., Feb. 20, 2014 /PRNewswire/ -- AbbVie today announced the launch of 'Perspectives - Art, Inflammation and Me', an initiative designed to add a different dimension to the current understanding of immune-mediated inflammatory diseases (IMIDs) and their impact on patients and society. More than 100 unique artistic expressions from the initiative are being debuted at the 9th Congress of the...